Send to

Choose Destination
Oncology. 2010;79(1-2):3-12. doi: 10.1159/000318529. Epub 2010 Nov 3.

Trimodal therapy for inflammatory breast cancer: a surgeon's perspective.

Author information

Department of Surgery, Radiology, Pathology and Medicine, Louisiana State University Health Sciences Center in Shreveport, and Feist-Weiller Cancer Center, Shreveport, La 71130, USA.


Inflammatory breast cancer (IBC) is a rare and most aggressive form of breast cancer. The onset and progression of disease are rapid; diagnosis must be made expediently to initiate treatment quickly. In this review, the clinical presentation, trimodal therapy, surgical principles and a brief summary of the Louisiana State University at Shreveport experience with IBC are presented. With this aggressive approach, 5-year survival of better than 40-50% can be expected. This represents a substantive improvement in clinical outcome for IBC patients compared with 30 years ago.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center